儿童致命性出血中使用抗纤溶药物的多中心前瞻性观察研究
本研究为MATIC研究数据集的二次分析,纳入美国、加拿大、意大利24家儿童医院0-17岁致命性出血患儿449例。比较出血事件期间接受抗纤溶药(氨甲环酸或氨基己酸)与未接受者的结局。抗纤溶药组6小时总死亡率(6% vs 17%,p=0.04)及出血所致6小时死亡率(4% vs 14%,p=0.04)显著更低;校正年龄、出血病因、PRISM评分和血浆缺口后,6小时和24小时死亡率仍降低(aOR 0.29,95%CI 0.09-0.93;aOR 0.45,95%CI 0.21-0.98)。
要点
- 儿童致命性出血接受抗纤溶药者6小时总死亡率6% vs 17%(p=0.04),出血所致6小时死亡率4% vs 14%(p=0.04)。
- 校正年龄、出血病因、PRISM评分和血浆缺口后,抗纤溶药组6小时死亡率aOR 0.29(95%CI 0.09-0.93),24小时死亡率aOR 0.45(95%CI 0.21-0.98)。
- 抗纤溶药组大量输血方案持续时间更长、血制品用量更大、接受因子VII更频繁。
- 本研究为观察性研究,不能确立因果关系,但支持在儿童致命性出血中考虑使用抗纤溶药。
适用人群与场景
- 0-17岁儿童,在6小时内接受超过40 mL/kg总血制品或在大容量输血方案激活下输血,且发生致命性出血事件。
- 来自美国、加拿大、意大利24家儿童医院的前瞻性观察性研究数据。
- 出血病因包括创伤(46%)、手术(34%)和内科原因(20%)。
诊断标准与关键阈值
- 致命性出血事件定义:6小时内接受超过40 mL/kg总血制品,或在大容量输血方案激活下输血。
- 原文未提及抗纤溶药启动或停止的具体阈值。
处置流程与药物剂量
- 在致命性出血事件期间,可考虑使用抗纤溶药物(氨甲环酸或氨基己酸);原文未提及具体剂量、给药途径、频次或疗程。
- 抗纤溶药组中18例使用ε-氨基己酸,35例使用氨甲环酸,1例两者均使用。
- 抗纤溶药组大量输血方案持续时间更长、血制品用量更大、接受因子VII更频繁。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:MATIC研究数据集的二次分析,前瞻性观察性多中心研究;24家儿童医院;449例患儿;中位年龄7岁(2-15岁),55%男性。
- 主要终点24小时死亡率:抗纤溶药组校正后aOR 0.45(95%CI 0.21-0.98;p=0.04)。
- 6小时死亡率:抗纤溶药组6% vs 非抗纤溶药组17%(p=0.04);出血所致6小时死亡率4% vs 14%(p=0.04);校正后6小时死亡率aOR 0.29(95%CI 0.09-0.93;p=0.04)。
- 抗纤溶药组与非抗纤溶药组基线人口学和生理参数可比,但抗纤溶药组大量输血方案持续时间更长、血制品用量更大、接受因子VII更频繁。
证据类型、等级与局限
- 证据类型:前瞻性观察性多中心研究的二次分析。
- 证据等级或推荐强度:原文未提及。
- 局限:观察性设计,不能确立因果关系;抗纤溶药组病情更重(大量输血方案持续时间更长、血制品用量更大、接受因子VII更频繁),可能存在残余混杂。
对床旁实践的改变
- 在儿童致命性出血事件中,应考虑使用抗纤溶药物(氨甲环酸或氨基己酸),因其与6小时和24小时死亡率降低独立相关。
- 适用人群:0-17岁儿童,符合致命性出血定义(6小时内接受超过40 mL/kg总血制品或在大容量输血方案激活下输血)。
- 常见陷阱:本研究为观察性研究,不能证明因果关系;抗纤溶药组接受了更多血制品和因子VII,提示病情更重,需谨慎解读。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To assess the impact of antifibrinolytics in children with life-threatening hemorrhage.
DESIGN: Secondary analysis of the MAssive Transfusion epidemiology and outcomes In Children study dataset, a prospective observational study of children with life-threatening bleeding events.
SETTING: Twenty-four children's hospitals in the United States, Canada, and Italy.
PATIENTS: Children 0-17 years old who received greater than 40 mL/kg of total blood products over 6 hours or were transfused under activation of massive transfusion protocol.
INTERVENTION/EXPOSURE: Children were compared according to receipt of antifibrinolytic medication (tranexamic acid or aminocaproic acid) during the bleeding event.
MEASUREMENTS AND MAIN RESULTS: Patient characteristics, medications administered, and clinical outcomes were analyzed using Cox proportional hazard and Kaplan-Meier survival analysis. The primary outcome was 24-hour mortality. Of 449 patients analyzed, median age was 7 years (2-15 yr), and 55% were male. The etiology of bleeding was 46% traumatic, 34% operative, and 20% medical. Twelve percent received antifibrinolytic medication during the bleeding event (n = 54 unique subjects; n = 18 epsilon aminocaproic acid, n = 35 tranexamic acid, and n = 1 both). The antifibrinolytic group was comparable with the nonantifibrinolytic group on baseline demographic and physiologic parameters; the antifibrinolytic group had longer massive transfusion protocol duration, received greater volume blood products, and received factor VII more frequently. In the antifibrinolytic group, there was significantly less 6-hour mortality overall (6% vs 17%; p = 0.04) and less 6-hour mortality due to hemorrhage (4% vs 14%; p = 0.04). After adjusting for age, bleeding etiology, Pediatric Risk of Mortality score, and plasma deficit, the antifibrinolytic group had decreased mortality at 6- and 24-hour postbleed (adjusted odds ratio, 0.29 [95% CI, 0.09-0.93]; p = 0.04 and adjusted odds ratio, 0.45 [95% CI, 0.21-0.98]; p = 0.04, respectively).
CONCLUSIONS: Administration of antifibrinolytic medications during the life-threatening event was independently associated with improved 6- and 24-hour survivals in bleeding children. Consideration should be given to use of antifibrinolytics in pediatric patients with life-threatening hemorrhage.
参考来源
- Spinella PC, Leonard JC, Gaines BA, et al. Use of Antifibrinolytics in Pediatric Life-Threatening Hemorrhage: A Prospective Observational Multicenter Study. Crit Care Med. 2022. PMID: 34661553. doi:10.1097/CCM.0000000000005383
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。